Lumida
/PRTA
⌘K
Prothena Corporation PLC

Prothena Corporation PLC

PRTA
$8.66USD+2.24%+0.19 today

MARKET CAP

453.4M

P/E (TTM)

FWD P/E

DAY RANGE

$8 – $9

52W RANGE

$6
$12

AI Summary

Stalk
TrimMedium

PRTA remains in a Stage 4 decline with a clear lower-high/lower-low sequence and price trading below its major moving averages. The recent short-covering rally has pushed price into declining 9/21/50 EMAs and verging on resistance at the 200DMA, creating an opportune zone to trim bearish positions. With medium- and long-term trends firmly down and overbought short-term indicators, fading this rally into moving-average resistance aligns with the prevailing downtrend.

  • Pipeline’s PRX-12 and Bertamumab anticipate top-line results Q4’24–Q2’25.
  • Closed Q4’23 with $621M cash, extending runway for pivotal trials into 2025.
  • 2024 op cash burn estimated at $208–225M strains liquidity runway.
Full analysis →
Insider Trades15 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Jan 24, 2024SellPRTAKarin L WalkerChief Accounting Officer10,000$23.77$453.4M-26.61%+38.78%$237.7K+0.00%10b5-1Trim
Dec 20, 2023SellPRTAKarin L WalkerChief Accounting Officer10,000$25.36$453.4M-26.61%+38.78%$253.6K+0.00%10b5-1Trim
Nov 30, 2023SellPRTAKarin L WalkerChief Accounting Officer10,000$23.77$453.4M-26.61%+38.78%$237.7K+0.00%10b5-1Trim
Oct 25, 2023SellPRTAKarin L WalkerChief Accounting Officer10,000$27.28$453.4M-26.61%+38.78%$272.8K+0.00%10b5-1Trim
Oct 11, 2023SellPRTABrandon S. SmithChief Operating Officer8,000$28.93$453.4M-26.61%+38.78%$231.5K+0.00%10b5-1Trim
Oct 4, 2023SellPRTACarol D. KarpChief Regulatory Officer10,000$29.38$453.4M-26.61%+38.78%